Cipla is gearing up for a major expansion in its product pipeline, outlining plans to launch seven new products by 2026 across high-growth therapeutic categories. The company will roll out four respiratory products and three peptide-based therapies, building on its established leadership in chronic care and inhalation treatment segments.
The respiratory portfolio expansion includes the launch of Gadvair in the fourth quarter of FY26. Cipla has filed three out of the four respiratory assets from its U.S. facilities as part of a risk-mitigation strategy aimed at ensuring regulatory and manufacturing continuity.
Alongside respiratory therapies, the drugmaker is set to introduce peptide products, including Liraglutide, reinforcing its diversification into advanced treatment platforms.
The development roadmap follows a steady financial performance in the September 2025 quarter. For Q2 FY26, Cipla reported revenue of ₹7,589.00 crore, an 8% year-on-year increase. EBITDA came in at ₹1,895.00 crore, up 0.50%, while profit after tax (PAT) rose 3.70% to ₹1,351.00 crore.
Cipla retains strong brand leadership in key categories, with Foracort ranked as the top respiratory brand in India and Albuterol commanding a 22% share of the U.S. MDI market. Its South Africa private market business is expanding at 1.3 times the sector growth rate.
With its planned respiratory and peptide launches, Cipla is preparing to reinforce its global position in the inhalation therapy space while broadening its footprint in chronic and specialty care.
